Endpoints News· Max Gelman·· 2 小时前AI 评分25
默沙东 R&D 负责人 Dean Li 称 sac-TMT 肿瘤项目已领先竞争对手
R&D chief Dean Li says Merck outflanked rivals with its sac-TMT cancer program
AI 导读
默沙东 R&D 负责人 Dean Li 表示，公司在 sac-TMT 肿瘤项目上已抢在竞争对手之前布局多个适应症。他认为这一项目使默沙东在下一代肿瘤药物竞争中占据先机。
正文 · 原文
Merck’s head of R&D Dean Li believes he’s outfoxed his competition for the next generation of oncology drugs, jumping into a wide set of indications …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news